Post navigation

A special Early Access to Medicines (EAMs) status has been granted in the UK to AbbVie’s as-yet-unapproved treatment for hepatitis C.

The glecaprevir/pibrentasivr (g/p) combination is a ‘pan-genotypic’ drug currently under review by the European Medicines Agency, and is part of a rapid evolution in treatments for the potentially deadly liver infection.

AbbVie is looking to compete with Gilead’s Epclusa, which was the first pan-genotypic hep C drug to hit the market last year.

The study is aimed at assessing the safety and immunogenicity of HCV prime-boost vaccinations ChAd3-hliNSmut and MVA-hliNSmut, administered intramuscularly in healthy volunteers and DAA treated patients. To read the entire study, click here Share This PageFollow Us … Continue reading → The post The study is aimed at assessing the safety and immunogenicity of HCV […]

The purpose of this study is to evaluate the efficacy and tolerability of DAA-based regimens in the clinical practice in HIV/HCV-coinfected patients. Hypothesis: The efficacy and tolerability of all DAA-based regimens in the clinical practice is different to what is … Continue reading → The post Real-life Security and Efficacy of DAA-based Therapy in 1,000 […]